Entos Pharmaceuticals Announces Research, Development and Collaboration Agreement
Entos Pharmaceuticals Inc., an Edmonton-based healthcare biotechnology company focused on the development of next generation nucleic acid-based therapies using their Fusogenix drug delivery platform, announced it has entered into a research, development and collaboration agreement with a clinical stage biopharmaceutical Partner focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.
- The biopharmaceutical development partner will remain anonymous due to competitive reasons.
- The companies will collaborate on the formulation and screening of candidates using Entos’ Fusogenix non-viral delivery platform for nucleic acid therapies.
- The biopharmaceutical partner has the option to exclusively license any candidates developed under this R&D agreement.
- If the option is exercised, Entos could receive up to US$109 million from the license agreement and undisclosed royalties on sales of products resulting from this collaboration.